FDA-approved drugs (crizotinib and entrectinib) for NSCLC that harbors ROS1 fusions significantly suppressed the growth of the lung tumoroids (Fig. 2m)21, indicating that such FDA-approved drugs will be effective on the patient in case unresectable lung tumors recur in this patient. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.